Topical compositions comprising polyunsaturated fatty acids
The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.
1. A topical monotherapy composition comprising:
at least one excipient; and
a polyunsaturated fatty acid (PUFA) derivative of formula (I):
or a salt thereof, wherein:
-Alk- is:
—(CH 2 ) 3 -[cis]CH═CH—CH 2 -[cis]CH═CH—CH 2 -[cis]CH═CH—;
R 1 is a hydrogen atom;
wherein the PUFA derivative is in the form of a racemate, a stereoisomer or a mixture of stereoisomers; and
wherein the topical monotherapy composition is substantially free of glucocorticoids.
2. The topical composition of claim 1 , wherein the PUFA derivative is present as the R enantiomer.
3. The topical composition of claim 1 , wherein the PUFA derivative is present as the S enantiomer.
4. The topical composition of claim 1 , wherein the excipient comprises a preservative selected from methylparaben, propylparaben, benzyl alcohol, ascorbyl palmitate, ascorbic acid, or any combination thereof.
5. The topical composition of claim 1 , wherein the excipient comprises an emollient, an emulsifier, a thickener, a preservative, or any combination thereof.
6. The topical composition of claim 1 , wherein the excipient comprises a solubilizing agent, a humectant, or any combination thereof.
7. The topical composition of claim 1 , wherein the topical composition is in the form of a cream.
8. The topical composition of claim 1 , wherein the topical composition is substantially free of lithium salts.
9. The topical composition of claim 1 , wherein the composition comprises about 0.01 wt % to about 50 wt % DGLA.
10. A method of treating skin inflammation in a mammal comprising administering to skin of said mammal the topical monotherapy composition of claim 1 .
11. A method of treating pruritus in a subject in need thereof, the method comprising topically administering a therapeutically effective amount of a monotherapy composition of claim 1 to skin of the subject.
12. The method of claim 11 , wherein the composition comprises about 0.01 wt % to about 50 wt % DGLA.
13. The method of claim 11 , wherein the composition is co-administered with a corticosteroid selected from the group consisting of clobetasol diproprionate, betamethasone diproprionate, halbetasol proprionate, diflorasone diacetate, fluocinonide, halcinonide, amcinonide, desoximetasone, triamcinolone acetonide, mometasone furoate, fluticasone proprionate, fluocinolone acetonide, hydrocortisone valerate, hydrocortisone butyrate, triamcinalone acetonide, desonide, prednicarbate, prednisolone, methylprednisolone, dexamethasone, naflocort, deflazacort, halopredone acetate, budesonide, beclomethasone dipropionate, hydrocortisone, clocortolone pivalate, methylprednisolone aceponate, dexamethasone palmitoate, tipredane, hydrocortisone aceponate, alclometasone dipropionate, halometasone, methylprednisolone suleptanate, rimexolone, prednisolone farnesylate, ciclesonide, deprodone propionateloteprednol etabonate, betamethasone butyrate propionate, flunisolide, prednisone, dexamethasone sodium phosphate, triamcinolone, betamethasone 17-valerate, betamethasone, betamethasone dipropionate, hydrocortisone acetate, hydrocortisone sodium succinate, prednisolone sodium phosphate, hydrocortisone probutate, and combinations thereof.
14. The method of claim 11 , wherein the composition is co-administered with a further therapeutic agent selected from the group consisting of immunomodulators, antibiotics, immunosuppressants, and anti-itch drugs.